[go: up one dir, main page]

SG11201809875VA - Compositions and methods for treating spinal muscular atrophy - Google Patents

Compositions and methods for treating spinal muscular atrophy

Info

Publication number
SG11201809875VA
SG11201809875VA SG11201809875VA SG11201809875VA SG11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA
Authority
SG
Singapore
Prior art keywords
international
methods
pct
spinal muscular
treating spinal
Prior art date
Application number
SG11201809875VA
Inventor
Ted Yednock
Sethu Sankaranarayanan
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of SG11201809875VA publication Critical patent/SG11201809875VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/196874 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) A61P 25/28 (2006.01) GO1N 33/53 (2006.01) (21) International Application Number: PCT/US2017/031801 (22) International Filing Date: 09 May 2017 (09.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/333,348 09 May 2016 (09.05.2016) US (71) Applicant: ANNEXON, INC. [US/US]; 180 Kimball Way, 2nd Floor, South San Francisco, CA 94080 (US). (72) Inventors: YEDNOCK, Ted; 184 Arroyo Road, For- est Knolls, CA 94333 (US). SANKARANARAYANAN, Sethu; 4720 Falstaff Avenue, Fremont, CA 94555 (US). (74) Agent: HALSTEAD, David, P. et al.; Foley Hoag — LLP, Seaport West, 155 Seaport Boulevard, Boston, MA = 02210-2600 (US). = _ (81) Designated States (unless otherwise indicated, for every — kind of national protection available): AE, AG, AL, AM, — AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, =— CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, KE, KG, KH, KN, KP, KR, JP, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States indicated, (84) (unless otherwise for every = kind ARIPO GH, = of regional protection available): (BW, _ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, _ = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, HR, HU, IE, IS, IT, LT, LU, LV, GB, GR, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = — TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = KM, ML, MR, NE, SN, TD, TG). — Published: ,- 1 — with international search report (Art. 21(3)) ..! — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of 71' IN amendments (Rule 48.2(h)) GC 0\ 1-1 IN 1-1 (54) Title: COMPOSITIONS AND METHODS FOR TREATING SPINAL MUSCULAR ATROPHY 0 ei (57) : The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating spinal muscular C atrophy, comprising administering to a subject an inhibitor of the complement pathway.
SG11201809875VA 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy SG11201809875VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333348P 2016-05-09 2016-05-09
PCT/US2017/031801 WO2017196874A1 (en) 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
SG11201809875VA true SG11201809875VA (en) 2018-12-28

Family

ID=60266798

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809875VA SG11201809875VA (en) 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy

Country Status (10)

Country Link
US (1) US20190161535A1 (en)
EP (1) EP3454901A4 (en)
JP (1) JP2019514994A (en)
KR (1) KR20190005944A (en)
CN (1) CN109475625A (en)
AU (1) AU2017264690A1 (en)
CA (1) CA3023667A1 (en)
IL (1) IL262830A (en)
SG (1) SG11201809875VA (en)
WO (1) WO2017196874A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016000106B1 (en) 2013-07-09 2023-11-21 Annexon, Inc. ANTI-C1Q ANTIBODIES AND USES THEREOF, HYBRIDOMA CELL, PHARMACEUTICAL COMPOSITION AND METHODS FOR DETECTING SYNAPSES IN A BIOLOGICAL SAMPLE CROSS-REFERENCES TO RELATED REQUESTS
IL296130A (en) 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and their uses
WO2019137922A1 (en) * 2018-01-09 2019-07-18 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
US12258413B2 (en) * 2018-12-28 2025-03-25 Kyowa Kirin Co., Ltd. Bispecific antibody binding to TfR
WO2020254346A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
WO2020254343A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Digital biomarker
CN115996752B (en) * 2020-05-05 2025-04-01 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 Compositions and methods for treating epilepsy
US20230287416A1 (en) * 2020-07-31 2023-09-14 Ractigen Therapeutics Combinatory treatment of sma with sarna and mrna modulators
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof
WO2023114763A1 (en) 2021-12-13 2023-06-22 Annexon, Inc. Anti-complement factor c1q antibodies with single binding arms and uses thereof
CN118045206B (en) * 2024-04-12 2024-07-05 四川至善唯新生物科技有限公司 Pharmaceutical composition for treating spinal muscular atrophy and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011051A (en) * 2004-03-26 2007-04-13 Promics Pty Ltd TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS.
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007070375A2 (en) * 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
SI2646470T1 (en) * 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
WO2014186599A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
BR112016000106B1 (en) * 2013-07-09 2023-11-21 Annexon, Inc. ANTI-C1Q ANTIBODIES AND USES THEREOF, HYBRIDOMA CELL, PHARMACEUTICAL COMPOSITION AND METHODS FOR DETECTING SYNAPSES IN A BIOLOGICAL SAMPLE CROSS-REFERENCES TO RELATED REQUESTS
KR102626877B1 (en) * 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 Humanized Anti-Complement Factor C1Q Antibodies and Uses Thereof

Also Published As

Publication number Publication date
US20190161535A1 (en) 2019-05-30
JP2019514994A (en) 2019-06-06
WO2017196874A1 (en) 2017-11-16
EP3454901A1 (en) 2019-03-20
IL262830A (en) 2018-12-31
AU2017264690A1 (en) 2018-11-29
CN109475625A (en) 2019-03-15
KR20190005944A (en) 2019-01-16
CA3023667A1 (en) 2017-11-16
EP3454901A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201909949XA (en) Targeted immunotolerance
SG11201811432WA (en) Rna for cancer therapy
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201803906PA (en) Control of cellular redox levels
SG11201909011PA (en) Niraparib compositions
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201808306PA (en) Treatment of cancer with tg02
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201805001UA (en) Method of treating influenza a
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903659WA (en) Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications